Arena Pharmaceuticals Inc.'s Belviq (lorcaserin) launched last week, nearly a year after the obesity drug was approved by the FDA. (See BioWorld Today, June 28, 2012.) Read More
In the wake of the FDA's Oncology Drugs Advisory Committee (ODAC) 13-1 vote against the adequacy of AVEO Pharmaceuticals Inc.'s tivozanib, an inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in renal cell carcinoma (RCC) there were several losers: patients, the company and its staff. Read More
